Form 4: Beta Bionics Chief Medical Officer Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Steven Jon Russell, Chief Medical Officer of Beta Bionics, Inc., reports the acquisition of stock options and restricted stock units.
Summary
- On February 27, 2025, Steven Jon Russell, the Chief Medical Officer of Beta Bionics, Inc., acquired 35,000 shares of common stock and stock options for 52,000 shares.
- The 35,000 shares were received as a restricted stock unit award under the Issuer's 2025 Equity Incentive Plan.
- The options have an exercise price of $19.91 and vest in 36 equal monthly installments from February 27, 2025, expiring on February 26, 2035.
- Following these transactions, Russell directly owns 73,071 shares of common stock and options for 52,000 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. The sentiment is neutral to positive.
Positives
- The grant of restricted stock units and stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
- The vesting schedule of the options encourages long-term commitment from the executive.
Industry Context
Stock option and restricted stock grants are common compensation practices for executives in publicly traded companies, aligning their interests with shareholder value and incentivizing performance.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Companies like Medtronic and Abbott also use stock options and restricted stock units to incentivize their executives.
- The vesting schedule of 36 months is a typical vesting period for stock options.
Stakeholder Impact
- The stock option and restricted stock unit grants incentivize the Chief Medical Officer to improve company performance, potentially benefiting shareholders.
- The grants do not have an immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of transaction: Acquisition of common stock and stock options. |
| 02/27/2025 | Vesting start date for stock options. |
| 02/26/2035 | Expiration date for stock options. |
| 03/03/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.